News and Announcements
The Board of Directors of Coinmat AG receives prominent access
- Published August 12, 2019 12:00AM UTC
- Publisher Wholesale Investor
- Categories Company Updates
With Prof. Dr. Ralf Wandmacher, a well-known personality in blockchain technology and banking strengthens the Board of Directors of Coinmat AG.
Prof. Dr. Ralf Wandmacher is Professor of Finance and Entrepreneurship. He received his doctorate in finance from the University of Cape Town. He is Professor of Finance and Entrepreneurship at the Accadis University of allplied sciences. As a professor he has been teaching since 2017 in the areas of Digital Finance, Cryptocurrencies, Initial Coin Offerings, Multi-Factor Investing, Digital Asset Management, Corporate Governance: Executive Compensation, Shareholder Value Management, Applied Global Finance, Mergers & Acquisitions and Entrepreneurship.
Over the past decades Ralf Wandmacher has co-founded several of his own companies and is active in several companies as a board member or advisor, including Deutsche Börse. He is specialized in the areas of Tokenization – Asset to Token, Token Derivatives, ICO/STO – Tokenomics, Whitepaper, Regulation, Cryptocurrencies – Trading, Structuring and Asset Management.
Prior to his academic career, Mr. Wandmacher was a senior trader and managing director at Deutsche Bank and other financial institutions for several years.
About Coinmat AG
Coinmat® is the world’s first crypto ATM operator with a full financial license. With a self-developed cash flow transaction service (CTS), Coinmat is able to realize for the first time in the industry a complete functionality regarding the payment and withdrawal of cash for the customers of the crypto ATMs. As a first mover, Coinmat is ready for Blitzscaling.
Company Updates
From Outback to Boardroom: How SWAN Systems is Codifying Water Stewardship
From the arid deserts of Australia to the boardrooms of global tech giants, SWAN Systems is redefining water efficiency. By bridging the gap between field-level agronomics and autonomous irrigation control, the company is proving that “water-positive” targets can be met with science, data, and a 10x ROI commitment.
The Ferrari of Immunotherapy: Chimeric’s High-Stakes Race to Cure Cancer
In the high-stakes world of biotechnology, the most sophisticated weapon against cancer isn’t a new chemical compound but the patient’s own immune system, re-engineered with the precision of a high-performance engine. “This particular CAR T is like a Ferrari,” says Dr. Rebecca McQualter, CEO of Chimeric Therapeutics (ASX: CHM). “It’s got two big engines on […]
From Algae Pioneers to a Natural Revolution: The Second Act of WRS Bioproducts
As the US FDA prepares to phase out synthetic food colors by the end of 2026, WRS Bioproducts is stepping in to solve a looming supply crisis. Led by industry pioneer Harry Rosen, the company is leveraging 40 years of industrial algae farming expertise to scale production of natural, superior-quality beta-carotene, positioning itself as a vital supplier in the rapidly shifting global market for natural ingredients.
Backed By Leading Investment Groups and Family Offices
